HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on BioCardia (NASDAQ:BCDA) and maintained a price target of $25.
August 21, 2024 | 5:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on BioCardia, maintaining a $25 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $25 price target by a reputable analyst suggests a positive outlook for BioCardia, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100